Lucia Marquez-Valdepena, NP
Psychiatric/Mental Health · Santa Teresa, NMNPI 1689010282
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Novo Nordisk at 33.1% of the total. Reporting peaked in 2022 at $361 and has fallen 83.0% since, to $61 in 2025.
Across 63 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$318
- Johnson & Johnson$133
- Lilly USA, LLC$95
- AbbVie$86
- AstraZeneca$74
- Pfizer$61
- plus $193 from 8 others
What the payments were for
- Food & beverage$960100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $318 |
| Johnson & Johnson | 8 | $133 |
| Lilly USA, LLC | 6 | $95 |
| AbbVie | 4 | $86 |
| AstraZeneca | 5 | $74 |
| Pfizer | 4 | $61 |
| Boehringer Ingelheim | 3 | $58 |
| Bayer | 2 | $44 |
| GSK | 1 | $17 |
| Avion Pharmaceuticals | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Amgen | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Novartis | 1 | $13 |
How this compares
$960 in reported general payments places this provider in the 75th percentile of 228 psychiatric/mental health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 35 | $526 |
| Buspirone Hcl | 45 | $522 |
| Quetiapine Fumarate | 27 | $458 |
| Trazodone Hcl | 25 | $344 |
| Bupropion XlBupropion Hcl | 16 | $343 |
| Lurasidone Hcl | 11 | $323 |
| Bupropion Hcl SrBupropion Hcl | 28 | $318 |
| Alprazolam | 42 | $251 |
| Lamotrigine | 21 | $244 |
| Risperidone | 18 | $239 |
| Aripiprazole | 17 | $234 |
| Lithium Carbonate | 14 | $186 |
| Gabapentin | 11 | $167 |
| Escitalopram Oxalate | 13 | $153 |
| Sertraline Hcl | 15 | $96 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Santa Teresa
- Ayanna WilliamsRoswell$23K
- Martha SnowAlbuquerque$13K
- Rachel JoyceSanta Fe$13K
- Vernon OsbornGallup$12K
- Jacqueline TutonLas Cruces$10K
- Jimmy CalzadoRio Rancho$9K
- Mario HerreraLas Cruces$7K
- Heidi PattarozziLas Cruces$6K
- Lorena GarciaLas Cruces$6K
- Tiny AdamsAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.